Abbatis Bioceuticals Corp. Announces Launch Of Redesigned Corporate Website

Follow this company

Companies Mentioned

06/17/2014 [ACCESSWIRE]

Abattis Bioceuticals Corp. (OTCPINK: ATTBF) saw its share volume remain strong on June 17th with 1,316,503 shares exchanging hands, slightly higher than its three month daily average volume of 933,180 shares.

Abattis a specialty biotechnology company focused on cultivating, licensing, and marketing proprietary ingredients, bio-similar compounds, equipment, and consulting services to North American medicinal markets, today announced the launch of its newly redesigned corporate website.

"We are excited to launch our new corporate web presence," said Abattis Bioceuticals Corp. CEO Mike Withrow. "The new website is designed to better highlight our subsidiaries and partners, as well as provide investors with the latest information that they need to make informed decisions. We are committed to transparency and unlocking long-term value for our shareholders."

Their new website is

ATTBF closed the day at $.428, 15.18% higher than its previous close of $.3716. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

Amarantus Bioscience Holdings Adds Cavendish Global As Partner At Coalition For Concussion Treatment

Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS) saw its share volume soar on June 17th with 10,937,854 shares exchanging hands, more than double its three month daily average volume of 4,819,260 shares.

Just last week, Amarantus announced the addition of Cavendish Global as partner at the 3rd #C4CT (Coalition for Concussion Treatment) Concussion Awareness Summit, on Thursday, July 31, 2014 at the United Nations in New York City, NY. The summit will be focused on the emerging hypothesis that brain injury may increase the risk of Alzheimer's disease.

Mr. Michael Moffat, Cavendish co-founder and President explains, "Brain disorders affect more than 60 million Americans, that's more than one in four Americans suffering from mental illness or brain injury. From autism and Alzheimer's disease to traumatic brain injury (TBI) and post-traumatic stress (PTS), brain ailments cost the U.S. close to $1 trillion each year. Leading scientists have uncovered compelling evidence of the link between Traumatic Brain Injuries and Alzheimer's and Parkinson's disease." Moffat emphasizes, "Cancer and heart disease affect fewer people, yet receive three times more funding support than brain diseases. With recent advances in understanding the link between TBI and brain ailments, there has never been a better time for pro-social family offices and foundations to make a real difference by accelerating the development of new diagnostics and treatments through increased grant-giving and philanthropy in this important area. Cavendish is committed to help make this happen."

AMBS closed the day at $.116, 8.41% higher than its previous close of $.107. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

ACTC Plans To Up-List To Nasdaq By End Of Year

Advanced Cell Technology, Inc. (OTCQB: ACTC) saw its share volume remain steady on June 17th with 9,735,234 shares exchanging hands, slightly lower than its three month daily average volume of 10,727,865 shares.

In a conference call on June 9th, Advanced Cell Technology reiterated its plans to up-list to Nasdaq, reverse-split, and achieve a large capital raise by the end of the year.  This came as a relief to investors and shareholders alike, as shown by the daily share volume in the company.

Advanced Cell Technology, Inc., a biotechnology company, develops and commercializes human pluripotent stem cell technology in the field of regenerative medicine in the United States. The company is conducting various clinical trials for treating dry age-related macular degeneration and ocular therapies; and has a preclinical development pipeline focused on products for autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms, such as human embryonic stem cell and induced pluripotent stem cell platforms. The company's  intellectual property portfolio also comprise cell therapy research programs, such as ophthalmology programs, which include macular degeneration, photoreceptor progenitor, retinal ganglion cell progenitor, and corneal endothelial programs; and other programs, such as mesenchymal stem cell, neuroprotective biological, and platelet programs. As of March 27, 2014, it had 46 issued patents and 178 pending patent applications for the development of intellectual property portfolio.

ACTC closed the day at $.0526, 5.2% higher than its previous close of $.05. is one of the most talked about stock newsletters in the world. To receive 100% FREE stock alerts that have incredible potential, sign up here:

ABOUT US: issues momentum alerts on stocks that can provide gains to day traders. provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the newsletter and receiving alerts from a Pro-Active team of researchers. believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here:

Disclosure: is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.


Leave a comment...

Your Name